Management

Francois R. Martelet, M.D., CEO, was elected to the board of directors of the company, effective July 20, 2007, and was appointed as Chief Executive Officer and President of the company as of December 1, 2007. Throughout 2007, Dr. Martelet provided consulting services to clients in the life sciences and biotechnology industry. Dr. Martelet served as Vice-President and Global Franchise Head, Oncology at Merck & Co. from July 2005 through December 2006. From July 2003 through July 2005, Dr. Martelet was the Regional Pharma Head, Central & Eastern Europe, Middle East and Africa for Novartis Pharma, AG. Prior to that, Dr. Martelet served in various other senior officer positions within various units of Novartis Pharmaceutical, including leading the Oncology Business Units in Asia, Latin America, Central and Europe, the Middle East and Africa. Prior to joining Novartis, Dr. Martelet served in various oncology-related capacities with Schering-Plough International, Eli Lilly Corporation and F. Hoffman-la Roche, AG. Dr. Martelet received a Doctorate in Medicine with distinction and a Pharmaceutical Marketing Master's Degree in Business from Dijon University, France. He also holds a degree in Legal Medicine from R. Descartes University School of Medicine, Paris.

David Berd, M.D., Chief Medical Officer, joined the company in November 2004. He has been Professor of Medicine at Thomas Jefferson University since 1984. Dr. Berd is the inventor of the AC-Vaccine technology, and conducted all the clinical trials of the vaccine completed to date. He is the author of numerous published papers on the basic science and clinical testing of the vaccine. Dr. Berd is a board-certified medical oncologist, and received training at the University of Pennsylvania and Yale University School of Medicine.

Linda M. Romig, Director of Finance and Administration, was appointed in June 2008. Prior to accepting this position, Ms. Romig provided consulting services in the telecommunications, utility, and biopharmaceutical industries. From 1997 to 2006, Ms. Romig served as Finance Director/Director of Accounting/Controller for Ulticom, Inc., a provider of service enabling software for the telecommunications industry. Prior to holding this position, Ms. Romig was Controller for a division of Health Data, Inc., a provider of rehabilitation and nursing home care services. Prior to this position, Ms. Romig held Treasurer/Controller positions with companies specializing in adult medical and children day care services. Ms. Romig started her career at Peat Marwick Mitchell & Co. (now KPMG LLP), where she worked in the firm's audit practice. She received her B.S. degree in Accounting from the Pennsylvania State University in 1979, and is a certified public accountant.

Isabelle Fourthin, M.D., Chief Medical Officer EMEA, comes to AVAX with over thirteen years of experience in the pharmaceutical/biotech industry in Europe. Most recently she was Medical Director Oncology, with Merck & Co., Inc. based in Paris. Previously, she held a Chief Medical Officer Europe position for Ost-Developpement S.A., a subsidiary of Osteotech Inc., a global biotech and medical device company, and worked for Sanofi-Aventis as a Field Manager. Dr. Fourthin holds a Medical Degree from the University of Medicine of Clermont-Ferrand (France) and an MBA in International Management from a leading business school (ESSEC) in Paris, France.

Henry E. Schea III, Director of Global Quality and Regulatory Affairs since March 2002. Mr. Schea has over 20 years experience in research, product development, GMP manufacturing and quality control and assurance, with a focus on cell and gene therapies. From 1981-1991, Mr. Schea served in various manufacturing and quality control positions at Amgen. From 1991 through 2001, Mr. Schea developed quality systems for new biotech firms including Gene Medicine and Chimeric Therapies. Mr. Schea received his B.S. in Microbial Genetics from the University of Massachusetts in 1976.

Benoit Pinteur, Director and Responsible Pharmacist of the manufacturing facilities in France. Mr. Pinteur has over 15 years experience of pharmaceutical industry. Prior to joining the company he was the Quality Assurance manager and responsible Pharmacist deputy for Shrering-Plough Development Operations in France. From 1995 to 1999 Mr. Pinteur served in Quality Assurance position for Roche and specifically for written Chemical DMF and also for the qualification of SAP software. From 1993-1995 Mr Pinteur was international regulatory affairs assistant for Pierre FABRE Médicaments. Mr. Pinteur received a Doctorate in Pharmacy with distinction.

© 2008 AVAX Technologies, Inc. | Terms